266 Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC)

Sophie Wildsmith(AstraZeneca (United Kingdom)), Ross Stewart(AstraZeneca (United Kingdom)), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Melissa de los Reyes(AstraZeneca (Japan)), Wendy J. Levin(AstraZeneca (United States)), Rajiv Raja(AstraZeneca (United States)), Alexandra Drakaki(University of California, Los Angeles), Hannah Bye(Royal Marsden NHS Foundation Trust), Jill Walker(AstraZeneca (United Kingdom)), Anne L’Hernault(AstraZeneca (United Kingdom)), Joaquim Bellmunt(Dana-Farber Cancer Institute), Thomas Powles(Queen Mary University of London), Philip He(AstraZeneca (Japan)), Weimin Li(Sichuan University), Feng Xiao(Xijing Hospital), Qu Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Ashok Gupta
Regular and Young Investigator Award Abstracts
November 1, 2020
10.1136/jitc-2020-sitc2020.0266
Cited by 7

Related Papers

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k